Teriflunomide (Aubagio) (14 mg film-coated tablet)

The objective of this systematic review is to examine the beneficial and harmful effects of teriflunomide for the treatment of relapsing-remitting form of MS (RRMS)

Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa Canadian Agency for Drugs and Technologies in Health 2014, [2014]
Series:Common drug review, clinical review report
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:The objective of this systematic review is to examine the beneficial and harmful effects of teriflunomide for the treatment of relapsing-remitting form of MS (RRMS)
Item Description:Title from PDF caption. - "October 2014."
Physical Description:1 PDF file (xi, 101 pages) illustrations